<DOC>
	<DOC>NCT02771795</DOC>
	<brief_summary>A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC</brief_summary>
	<brief_title>A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Subjects have completed the study treatment of SB3G31BC. Subjects must provide informed consent. Subjects unwilling to follow the study requirements are not eligible for the study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HER2</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Biosimilar</keyword>
	<keyword>Cancer</keyword>
	<keyword>Breast</keyword>
	<keyword>Positive</keyword>
</DOC>